Loading
Showed that neoadjuvant immunotherapy can produce major pathologic responses in liver cancer.
Thomas U. Marron is Director of the Early Phase Trials Unit at The Mount Sinai Hospital and Tisch Cancer Institute. He is known for showing that neoadjuvant immunotherapy can produce major pathological responses in liver cancer, leading perioperative cemiplimab studies in hepatocellular carcinoma. His selected paper reports a single-arm phase 2 trial of neoadjuvant cemiplimab for resectable hepatocellular carcinoma. He runs Mount Sinai's early-phase unit and leads window-of-opportunity trials.
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial | Lancet Gastroenterology & Hepatology | 2022 |
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Hepatocellular carcinoma.
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Hepatocellular carcinoma.
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Neoadjuvant / adjuvant / perioperative.
Shares Neoadjuvant / adjuvant / perioperative, Hepatocellular carcinoma.
Shares Cemiplimab, Hepatocellular carcinoma.